| |
Week of Study
| |
---|
|
0
|
1
|
4
|
8
|
9
|
10
|
12
|
p-valueb
|
---|
CK, IU/L
| | | | | | | | |
Placebo
|
141 ± 12
|
582 ± 77
|
373 ± 13
|
246 ± 29
|
484 ± 52
|
528 ± 72
|
187 ± 21
| |
ATP
|
145 ± 8
|
500 ± 71
|
324 ± 14
|
234 ± 32
|
426 ± 44
|
449 ± 62
|
160 ± 20
|
0.91
|
24 h 3MH:Cr, μmol:mg
| | | | | | | |
Placebo
|
0.127 ± 0.007
|
0.130 ± 0.003
|
Nmc
|
0.123 ± 0.004
|
0.134 ± 0.005
|
0.152 ± 0.005
|
Nm
| |
ATP
|
0.136 ± 0.008
|
0.127 ± 0.007
|
Nm
|
0.143 ± 0.007#
|
0.143 ± 0.008
|
0.131 ± 0.012#
|
Nm
|
0.007
|
CRP, mg/L
| | | | | | | | |
Placebo
|
1.9 ± 0.7
|
1.1 ± 0.1
|
1.3 ± 0.3
|
2.0 ± 0.7
|
1.6 ± 0.7
|
1.2 ± 0.2
|
1.6 ± 0.4
| |
ATP
|
1.4 ± 0.4
|
1.1 ± 0.1
|
1.2 ± 0.2
|
1.9 ± 0.6
|
1.7 ± 0.6
|
1.1 ± 0.1
|
1.2 ± 0.2
|
0.99
|
Cortisol, μg/dL
| | | | | | | | |
Placebo
|
19.7 ± 1.1
|
20.8 ± 1.3
|
19.0 ± 1.2
|
19.2 ± 0.4
|
22.0 ± 0.4
|
23.6 ± 0.3
|
20.3 ± 0.6
| |
ATP
|
20.9 ± 1.2
|
20.5 ± 1.3
|
18.4 ± 1.4
|
19.0 ± 0.4
|
21.5 ± 0.4
|
22.6 ± 0.2
|
19.7 ± 0.6
|
0.86
|
Free Testosterone, ng/dL
| | | | | | | | |
Placebo
|
103 ± 13
|
112 ± 10
|
119 ± 6
|
111 ± 9
|
98 ± 6
|
100 ± 9
|
113 ± 12
| |
ATP
|
112 ± 13
|
114 ± 9
|
118 ± 6
|
117 ± 11
|
108 ± 7
|
110 ± 10
|
125 ± 13
|
0.93
|
Total Testosterone, ng/dL
| | | | | | | | |
Placebo
|
591 ± 73
|
620 ± 58
|
625 ± 55
|
585 ± 58
|
551 ± 46
|
536 ± 88
|
605 ± 72
| |
ATP
|
660 ± 67
|
645 ± 54
|
695 ± 60
|
645 ± 60
|
621 ± 49
|
592 ± 84
|
673 ± 69
|
0.83
|
PRSd
| | | | | | | | |
Placebo
|
9.1 ± 0.3
|
4.7 ± 0.4
|
7.0 ± 0.3
|
7.6 ± 0.2
|
4.8 ± 0.3
|
4.4 ± 0.3
|
7.6 ± 0.2
| |
ATP
|
9.6 ± 0.2
|
4.9 ± 0.4
|
7.5 ± 0.3
|
8.2 ± 0.3
|
5.5 ± 0.4
|
5.5 ± 0.4
|
8.6 ± 0.4
|
0.61
|
- aMean ± SEM for n = 11 ATP (400 mg ATP/d taken 30 min prior to exercise) and n = 10 placebo supplemented participants.
- bProbability of treatment by time difference between the placebo and the ATP treatments over the 12-week study. The mixed model in SAS® was used with the main effects of treatment, week and treatment by week, with the value for week 0 used as a covariate. The mixed model in SAS® was also used for 3MH:Cr: however, 3MH:Cr was measured only at weeks 0, 1, 8, 9, and 10. The model used these values with week 0 as a covariate for determining the overall treatment by time effect for 3MH:Cr.
- cNot measured.
- dPerceived recovery score is rated on the participants feeling of recovery from the last workout on a scale of 0-10. 0-2 indicates poor recovery and an anticipated decline in performance; 4-6 indicates low to moderate recovery and expected similar performance; and 8-10 indicates highly perceived recovery and expected increases in performance.
- #Significantly different than corresponding placebo, t-test (p < 0.05).